1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Announces Plan for Return of $375 Million in Excess Capital
Announces Participation at Upcoming Healthcare Conferences
U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
Investor Presentation
Reports Second Quarter 2025 Financial Results
Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Changes in Board, Management or Compensation
Shareholder votes, Other Events
Q2
Q1
FY 2023
Q3
SC TO-I
Tender Offer Statement by Issuer
Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership